Cervical cancer is the fourth most frequently occurring cancer in women around the world and can affect them during their reproductive years. Since the development of the Papanicolaou (Pap) test, screening has been essential in identifying cervical cancer at a treatable stage. With the identification of the human papillomavirus (HPV) as the causative agent of essentially all cervical cancer cases, HPV molecular screening tests and HPV vaccines for primary prevention against the virus have been developed. Accordingly, comparative studies were designed to assess the performance of cervical cancer screening methods in order to devise the best screening strategy possible. This review critically assesses the current cervical cancer screening methods as well as the implementation of HPV vaccination in Europe. The most recent European Guidelines and recommendations for organized population-based programs with HPV testing as the primary screening method are also presented. Lastly, the current landscape of cervical cancer screening programs is assessed for both European Union member states and some associated countries, in regard to the transition towards population-based screening programs with primary HPV testing.
In: Marshall , A D , Cunningham , E B , Nielsen , S , Aghemo , A , Alho , H , Backmund , M , Bruggmann , P , Dalgard , O , Seguin-Devaux , C , Flisiak , R , Foster , G R , Gheorghe , L , Goldberg , D , Goulis , I , Hickman , M , Hoffmann , P , Jancoriene , L , Jarcuska , P , Kåberg , M , Kostrikis , L G , Makara , M , Maimets , M , Marinho , R T , Maticic , M , Norris , S , Ólafsson , S , Øvrehus , A , Pawlotsky , J-M , Pocock , J , Robaeys , G , Roncero , C , Simonova , M , Sperl , J , Tait , M , Tolmane , I , Tomaselli , S , van der Valk , M , Vince , A , Dore , G J , Lazarus , J V & Grebely , J 2018 , ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ' , The Lancet Gastroenterology & Hepatology , vol. 3 , no. 2 , pp. 125–133 . https://doi.org/10.1016/S2468-1253(17)30284-4
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.
In: Marshall , A D , Cunningham , E B , Nielsen , S , Aghemo , A , Alho , H , Backmund , M , Bruggmann , P , Dalgard , O , Seguin-Devaux , C , Flisiak , R , Foster , G R , Gheorghe , L , Goldberg , D , Goulis , I , Hickman , M , Hoffmann , P , Jancorienė , L , Jarcuska , P , Kåberg , M , Kostrikis , L G , Makara , M , Maimets , M , Marinho , R T , Matičič , M , Norris , S , Ólafsson , S , Øvrehus , A , Pawlotsky , J-M , Pocock , J , Robaeys , G , Roncero , C , Simonova , M , Sperl , J , Tait , M , Tolmane , I , Tomaselli , S , van der Valk , M , Vince , A , Dore , G J , Lazarus , J V , Grebely , J 2018 , ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ' , Lancet Gastroenterology and Hepatology , vol. 3 , no. 2 , pp. 125–133 . https://doi.org/10.1016/S2468-1253(17)30284-4
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.
In: Marshall , A D , Cunningham , E B , Nielsen , S , Aghemo , A , Alho , H , Backmund , M , Bruggmann , P , Dalgard , O , Seguin-Devaux , C , Flisiak , R , Foster , G R , Gheorghe , L , Goldberg , D , Goulis , I , Hickman , M , Hoffmann , P , Jancorienė , L , Jarcuska , P , Kåberg , M , Kostrikis , L G , Makara , M , Maimets , M , Marinho , R T , Matičič , M , Norris , S , Ólafsson , S , Øvrehus , A , Pawlotsky , J-M , Pocock , J , Robaeys , G , Roncero , C , Simonova , M , Sperl , J , Tait , M , Tolmane , I , Tomaselli , S , van der Valk , M , Vince , A , Dore , G J , Lazarus , J V , Grebely , J & International Network on Hepatitis in Substance Users (INHSU) 2018 , ' Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe ' , The Lancet Gastroenterology & Hepatology , vol. 3 , no. 2 , pp. 125-133 . https://doi.org/10.1016/S2468-1253(17)30284-4
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) ; Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when the virus had already established a pandemic. For at least three decades the epidemic in the Western World has been dominated by subtype B infections, as part of a sub-epidemic that traveled from Africa through Haiti to United States. However, the pattern of the subsequent spread still remains poorly understood. Here we analyze a large dataset of globally representative HIV-1 subtype B strains to map their spread around the world over the last 50years and describe significant spread patterns. We show that subtype B travelled from North America to Western Europe in different occasions, while Central/Eastern Europe remained isolated for the most part of the early epidemic. Looking with more detail in European countries we see that the United Kingdom, France and Switzerland exchanged viral isolates with non-European countries than with European ones. The observed pattern is likely to mirror geopolitical landmarks in the post-World War II era, namely the rise and the fall of the Iron Curtain and the European colonialism. In conclusion, HIV-1 spread through specific migration routes which are consistent with geopolitical factors that affected human activities during the last 50 years, such as migration, tourism and trade. Our findings support the argument that epidemic control policies should be global and incorporate political and socioeconomic factors. ; info:eu-repo/semantics/publishedVersion
Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when the virus had already established a pandemic. For at least three decades the epidemic in the Western World has been dominated by subtype B infections, as part of a sub-epidemic that traveled from Africa through Haiti to United States. However, the pattern of the subsequent spread still remains poorly understood. Here we analyze a large dataset of globally representative HIV-1 subtype B strains to map their spread around the world over the last 50 years and describe significant spread patterns. We show that subtype B travelled from North America to Western Europe in different occasions, while Central/Eastern Europe remained isolated for the most part of the early epidemic. Looking with more detail in European countries we see that the United Kingdom, France and Switzerland exchanged viral isolates with non-European countries than with European ones. The observed pattern is likely to mirror geopolitical landmarks in the post-World War II era, namely the rise and the fall of the Iron Curtain and the European colonialism. In conclusion, HIV-1 spread through specific migration routes which are consistent with geopolitical factors that affected human activities during the last 50 years, such as migration, tourism and trade. Our findings support the argument that epidemic control policies should be global and incorporate political and socioeconomic factors.
Human immunodeficiency virus type 1 (HIV-1) was discovered in the early 1980s when the virus had already established a pandemic. For at least three decades the epidemic in the Western World has been dominated by subtype B infections, as part of a sub-epidemic that traveled from Africa through Haiti to United States. However, the pattern of the subsequent spread still remains poorly understood. Here we analyze a large dataset of globally representative HIV-1 subtype B strains to map their spread around the world over the last 50 years and describe significant spread patterns. We show that subtype B travelled from North America to Western Europe in different occasions, while Central/Eastern Europe remained isolated for the most part of the early epidemic. Looking with more detail in European countries we see that the United Kingdom, France and Switzerland exchanged viral isolates with non-European countries than with European ones. The observed pattern is likely to mirror geopolitical landmarks in the post-World War II era, namely the rise and the fall of the Iron Curtain and the European colonialism. In conclusion, HIV-1 spread through specific migration routes which are consistent with geopolitical factors that affected human activities during the last 50 years, such as migration, tourism and trade. Our findings support the argument that epidemic control policies should be global and incorporate political and socioeconomic factors.